SLC5A2 and type 2 diabetes mellitus: Dapagliflozin (Farxiga®) is a medication that lowers blood glucose levels in individuals with T2D via inhibition of renal glucose reabsorption through blockade of sodium-glucose cotransporter 2 (SGLT2) which increases urinary glucose excretion [13].